These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 17339973)
1. Ovarian cancer screening. Neesham D Aust Fam Physician; 2007 Mar; 36(3):126-8. PubMed ID: 17339973 [TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer screening: a look at the evidence. Fields MM; Chevlen E Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731 [TBL] [Abstract][Full Text] [Related]
3. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
4. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. Evans DG; Gaarenstroom KN; Stirling D; Shenton A; Maehle L; Dørum A; Steel M; Lalloo F; Apold J; Porteous ME; Vasen HF; van Asperen CJ; Moller P J Med Genet; 2009 Sep; 46(9):593-7. PubMed ID: 18413372 [TBL] [Abstract][Full Text] [Related]
5. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Olivier RI; Lubsen-Brandsma MA; Verhoef S; van Beurden M Gynecol Oncol; 2006 Jan; 100(1):20-6. PubMed ID: 16188302 [TBL] [Abstract][Full Text] [Related]
6. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Gilbert L; Basso O; Sampalis J; Karp I; Martins C; Feng J; Piedimonte S; Quintal L; Ramanakumar AV; Takefman J; Grigorie MS; Artho G; Krishnamurthy S; Lancet Oncol; 2012 Mar; 13(3):285-91. PubMed ID: 22257524 [TBL] [Abstract][Full Text] [Related]
7. [Screening pelvic tumours for hereditary risk of ovarian neoplasms, a cancer center experience]. Taïeb S; Rocourt N; Narducci F; Leblanc E; Adenis C; Fournier C; Doutrelant P; Peyrat JP; Vennin P Bull Cancer; 2011 Feb; 98(2):113-9. PubMed ID: 21339094 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Menon U; Gentry-Maharaj A; Hallett R; Ryan A; Burnell M; Sharma A; Lewis S; Davies S; Philpott S; Lopes A; Godfrey K; Oram D; Herod J; Williamson K; Seif MW; Scott I; Mould T; Woolas R; Murdoch J; Dobbs S; Amso NN; Leeson S; Cruickshank D; McGuire A; Campbell S; Fallowfield L; Singh N; Dawnay A; Skates SJ; Parmar M; Jacobs I Lancet Oncol; 2009 Apr; 10(4):327-40. PubMed ID: 19282241 [TBL] [Abstract][Full Text] [Related]
9. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Oei AL; Massuger LF; Bulten J; Ligtenberg MJ; Hoogerbrugge N; de Hullu JA Br J Cancer; 2006 Mar; 94(6):814-9. PubMed ID: 16495917 [TBL] [Abstract][Full Text] [Related]
10. Screening for ovarian cancer. Quinn MA Aust Fam Physician; 2001 Jun; 30(6):530-4. PubMed ID: 11458578 [TBL] [Abstract][Full Text] [Related]
11. No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Hermsen BB; Olivier RI; Verheijen RH; van Beurden M; de Hullu JA; Massuger LF; Burger CW; Brekelmans CT; Mourits MJ; de Bock GH; Gaarenstroom KN; van Boven HH; Mooij TM; Rookus MA Br J Cancer; 2007 May; 96(9):1335-42. PubMed ID: 17426707 [TBL] [Abstract][Full Text] [Related]
12. Screening for ovarian cancer: what we know, what we need to know. Hensley ML; Castiel M; Robson ME Oncology (Williston Park); 2000 Nov; 14(11):1601-7; discussion 1608, 1613-6. PubMed ID: 11125943 [TBL] [Abstract][Full Text] [Related]
13. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA; JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424 [TBL] [Abstract][Full Text] [Related]
14. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? van der Velde NM; Mourits MJ; Arts HJ; de Vries J; Leegte BK; Dijkhuis G; Oosterwijk JC; de Bock GH Int J Cancer; 2009 Feb; 124(4):919-23. PubMed ID: 19035463 [TBL] [Abstract][Full Text] [Related]
16. Screening for ovarian cancer in the general population. Chu CS; Rubin SC Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690 [TBL] [Abstract][Full Text] [Related]
17. A comprehensive look at the early detection of ovarian cancer. O'Rourke J; Mahon SM Clin J Oncol Nurs; 2003; 7(1):41-7. PubMed ID: 12629933 [TBL] [Abstract][Full Text] [Related]
19. Ovarian cancer screening in women with a family history of breast or ovarian cancer. Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240 [TBL] [Abstract][Full Text] [Related]
20. [Screening for ovarian cancer in BRCA1/BRCA2 mutations carriers]. Synowiec A; Wcisło G; Bodnar L; Gasowska-Bodnar A; Szczylik C Ginekol Pol; 2014 May; 85(5):377-81. PubMed ID: 25011220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]